A Drugmaker’s Stock is Getting Crushed After a Peanut-Allergy Patch Failed a Key Study

Photo via CBS New York

A possible treatment for one of the most common food allergies in the world just failed a fundamental trial.

Approximately 1.5 million children in the United States are allergic to peanuts, an allergy that can usually be so severe that even the scantiest amount of contact can set off an extreme reaction.

To counter that, DBV Technologies has been developing a patch that is designed to reduce that severity of the allergic reaction.

However, during a late-stage trial, DBV was not able to hit a fundamental statistic measurement that is required to consider the trial a success.

DBV stated that of the patients who became part of the trial, 35 percent of those who used the patch responded after a year, while 13.6 percent of those who used the placebo patch responded. Responding to the treatment either implied that they could be exposed to a certain amount of more peanut protein than when they began the trial.

DBV said that it still plans to continue toward submitting the data to the Food and Drug Administration (FDA) for approval. Following the news, the stock of DBV was down to as much as 60 percent on Friday.

“We believe that this preliminary analysis shows significant therapeutic promise in the peanut-allergic population, where there is a high unmet medical need and no approved treatments,” said Dr. Pierre-Henri Benhamou, the DBV CEO, in a statement.